| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910815 | Lung Cancer | 2015 | 6 Pages |
Abstract
We observed equivalent OS among patients with limited-stage SCLC being treated with three dose-fractionation regimens of concurrent CRT. This supports the use of any one of these regimens while awaiting the results of ongoing randomized trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Charles E. Rutter, Henry S. Park, Christopher D. Corso, Debra N. Yeboa, Brandon R. Mancini, Nataniel H. Lester-Coll, Anthony W. Kim, Roy H. Decker,